scispace - formally typeset
B

Barry P. Rosen

Researcher at FIU Herbert Wertheim College of Medicine

Publications -  548
Citations -  39801

Barry P. Rosen is an academic researcher from FIU Herbert Wertheim College of Medicine. The author has contributed to research in topics: Arsenite & Arsenic. The author has an hindex of 102, co-authored 529 publications receiving 36258 citations. Previous affiliations of Barry P. Rosen include Wayne State University & North China Electric Power University.

Papers
More filters
Journal ArticleDOI

Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Ganna Chornokur, +158 more
- 19 Jun 2015 - 
TL;DR: Associations between inherited cellular transport gene variants and risk of EOC histologic subtypes are revealed on a large cohort of women.
Journal ArticleDOI

Prevalence and Penetrance of Germline BRCA1 and BRCA2 Mutations in a Population Series of 649 Women with Ovarian Cancer

TL;DR: Risks of ovarian, breast, and stomach cancers and leukemias/lymphomas were increased nine-, five-, six- and threefold, respectively, among first-degree relatives of cases carrying BRCA1 mutations, compared with relatives of noncarriers, and risk of colorectal cancer was increased threefold for relatives of Cases carrying B RCA2 mutations.
Journal ArticleDOI

Biochemistry of arsenic detoxification

TL;DR: While the overall schemes for arsenic resistance are similar in prokaryotes and eukaryotes, some of the specific proteins are the products of separate evolutionary pathways.
Journal ArticleDOI

Microbial arsenic: from geocycles to genes and enzymes.

TL;DR: The DNA sequencing and protein crystal structures have established the convergent evolution of three classes of arsenate reductases, which involve three cysteine thiols and S-As bond intermediates, so convergence evolution to similar mechanisms has taken place.
Journal ArticleDOI

Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada

TL;DR: BRCA1 and BRCA2 mutations may be more frequent in general populations than previously thought and may be associated with various types of cancers.